Fluoroquinolones and the Risk of Aortic Aneurysm or Aortic Dissection: A Systematic Review and Meta-Analysis.

Q2 Medicine
Prashanth Rawla, Marie Line El Helou, Anantha R Vellipuram
{"title":"Fluoroquinolones and the Risk of Aortic Aneurysm or Aortic Dissection: A Systematic Review and Meta-Analysis.","authors":"Prashanth Rawla,&nbsp;Marie Line El Helou,&nbsp;Anantha R Vellipuram","doi":"10.2174/1871525717666190402121958","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>We performed a systematic review and meta-analysis to explore the risk of an aortic aneurysm or aortic dissection following fluoroquinolone administration.</p><p><strong>Methods: </strong>PubMed, Cochrane library, ClinicalTrials.gov, Embase and Google Scholar were systematically reviewed for controlled studies including adult patients exposed to fluoroquinolones with a primary outcome of aortic aneurysm or aortic dissection.</p><p><strong>Results: </strong>The meta-analysis was conducted by pooling the effect estimates of four controlled observational studies (one case-control, one case-crossover and two cohort studies). Fluoroquinolone administration more than doubled the risk to develop aortic aneurysm or aortic dissection within 60 days following fluoroquinolone exposure (adjusted Relative Risk [RR] (95% confidence interval [CI]) = 2.14 (1.93 - 2.36); I2 = 15.8%). The quality of the finding was rated as moderate. The risk increase for aortic aneurysm alone was found to be significant (adjusted RR (95% CI) = 2.23 (2.01 - 2.45); I2 = 0%) while the risk increase for aortic dissection alone was not found to be significant (adjusted RR = 1.88 (0.11 - 3.65); I2 = 74%). In subgroup analysis, the risk increase for aortic aneurysm or aortic dissection appeared to be higher in females compared to males (RR = 1.87 (1.24 - 2.51); I2 = 0% versus RR = 1.58 (1.25 - 1.92); I2 = 0%, respectively) and higher in older patients compared to younger patients (RR = 1.72 (1.37 - 2.07); I2 = 0% versus RR = 1.47 (0.91 - 2.04); I2 = 0%, respectively). Subgroup analysis of two studies which measured the duration-response analysis found that as the duration of fluoroquinolone therapy increased from 3 to 14 days to greater than 14 days, there was an increased risk of aortic aneurysm or dissection.</p><p><strong>Conclusion: </strong>The findings of this meta-analysis confirm the positive association between fluoroquinolones and the development of aortic aneurysm or dissection. The data tend to show that this association may be majorly driven by aortic aneurysm. Additionally, some risk factors appear to prevail including prolonged fluoroquinolone treatment and older age.</p>","PeriodicalId":9535,"journal":{"name":"Cardiovascular and Hematological Agents in Medicinal Chemistry","volume":"17 1","pages":"3-10"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1871525717666190402121958","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Agents in Medicinal Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871525717666190402121958","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 14

Abstract

Objectives: We performed a systematic review and meta-analysis to explore the risk of an aortic aneurysm or aortic dissection following fluoroquinolone administration.

Methods: PubMed, Cochrane library, ClinicalTrials.gov, Embase and Google Scholar were systematically reviewed for controlled studies including adult patients exposed to fluoroquinolones with a primary outcome of aortic aneurysm or aortic dissection.

Results: The meta-analysis was conducted by pooling the effect estimates of four controlled observational studies (one case-control, one case-crossover and two cohort studies). Fluoroquinolone administration more than doubled the risk to develop aortic aneurysm or aortic dissection within 60 days following fluoroquinolone exposure (adjusted Relative Risk [RR] (95% confidence interval [CI]) = 2.14 (1.93 - 2.36); I2 = 15.8%). The quality of the finding was rated as moderate. The risk increase for aortic aneurysm alone was found to be significant (adjusted RR (95% CI) = 2.23 (2.01 - 2.45); I2 = 0%) while the risk increase for aortic dissection alone was not found to be significant (adjusted RR = 1.88 (0.11 - 3.65); I2 = 74%). In subgroup analysis, the risk increase for aortic aneurysm or aortic dissection appeared to be higher in females compared to males (RR = 1.87 (1.24 - 2.51); I2 = 0% versus RR = 1.58 (1.25 - 1.92); I2 = 0%, respectively) and higher in older patients compared to younger patients (RR = 1.72 (1.37 - 2.07); I2 = 0% versus RR = 1.47 (0.91 - 2.04); I2 = 0%, respectively). Subgroup analysis of two studies which measured the duration-response analysis found that as the duration of fluoroquinolone therapy increased from 3 to 14 days to greater than 14 days, there was an increased risk of aortic aneurysm or dissection.

Conclusion: The findings of this meta-analysis confirm the positive association between fluoroquinolones and the development of aortic aneurysm or dissection. The data tend to show that this association may be majorly driven by aortic aneurysm. Additionally, some risk factors appear to prevail including prolonged fluoroquinolone treatment and older age.

Abstract Image

Abstract Image

Abstract Image

氟喹诺酮类药物与主动脉瘤或主动脉夹层的风险:系统综述和荟萃分析。
目的:我们进行了一项系统回顾和荟萃分析,以探讨氟喹诺酮类药物治疗后动脉瘤或主动脉夹层的风险。方法:系统回顾PubMed、Cochrane图书馆、ClinicalTrials.gov、Embase和Google Scholar,纳入以主动脉瘤或主动脉夹层为主要结局的成年氟喹诺酮类药物暴露患者的对照研究。结果:荟萃分析是通过汇总4项对照观察性研究(1项病例对照研究、1项病例交叉研究和2项队列研究)的效果估计进行的。氟喹诺酮类药物暴露后60天内发生主动脉瘤或主动脉夹层的风险增加一倍以上(校正相对危险度[RR](95%可信区间[CI]) = 2.14 (1.93 - 2.36);I2 = 15.8%)。研究结果的质量被评为中等。单独动脉瘤的风险增加显著(校正后RR (95% CI) = 2.23 (2.01 - 2.45);I2 = 0%),而单独主动脉夹层的风险增加无显著性(校正后RR = 1.88 (0.11 - 3.65);I2 = 74%)。在亚组分析中,女性患主动脉瘤或主动脉夹层的风险增加似乎高于男性(RR = 1.87 (1.24 - 2.51);I2 = 0%, RR = 1.58 (1.25 - 1.92);I2 = 0%),老年患者比年轻患者更高(RR = 1.72 (1.37 - 2.07);I2 = 0%, RR = 1.47 (0.91 - 2.04);I2 = 0%)。对两项测量持续时间-反应分析的研究进行亚组分析发现,随着氟喹诺酮类药物治疗时间从3 ~ 14天增加到14天以上,发生主动脉瘤或夹层的风险增加。结论:本荟萃分析的结果证实氟喹诺酮类药物与主动脉瘤或夹层的发展呈正相关。数据倾向于表明这种关联可能主要是由主动脉瘤引起的。此外,一些风险因素似乎普遍存在,包括长期氟喹诺酮类药物治疗和年龄较大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiovascular and Hematological Agents in Medicinal Chemistry
Cardiovascular and Hematological Agents in Medicinal Chemistry Medicine-Cardiology and Cardiovascular Medicine
CiteScore
2.70
自引率
0.00%
发文量
34
期刊介绍: Cardiovascular & Hematological Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new Cardiovascular & Hematological Agents. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Cardiovascular & Hematological medicinal chemistry. Cardiovascular & Hematological Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cardiovascular & hematological drug discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信